S S Connolly1, F T D'Arcy, M O Corcoran. 1. Department of Urology, University College Hospital Galway, Galway, Ireland. steconnolly@rcsi.ie
Abstract
INTRODUCTION: The use of recombinant activated factor VII has been described for many clinical scenarios, but the value of this therapeutic agent for life-threatening haemorrhagic cystitis remains novel. METHOD: We describe a case of persistent life-threatening haemorrhagic radiation cystitis, and discuss current knowledge of this therapy including potential complications. RESULT: Control of haemorrhage was successfully achieved only after use of this agent. CONCLUSION: This therapy deserves mention in any future management algorithm devised for this condition.
INTRODUCTION: The use of recombinant activated factor VII has been described for many clinical scenarios, but the value of this therapeutic agent for life-threatening haemorrhagic cystitis remains novel. METHOD: We describe a case of persistent life-threatening haemorrhagic radiation cystitis, and discuss current knowledge of this therapy including potential complications. RESULT: Control of haemorrhage was successfully achieved only after use of this agent. CONCLUSION: This therapy deserves mention in any future management algorithm devised for this condition.
Authors: Philip W Friederich; Christiaan P Henny; Embert J Messelink; Mark G Geerdink; Tymen Keller; Karl-Heinz Kurth; Harry R Büller; Marcel Levi Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: A Zaman Khan; J Michael Parry; William F Crowley; K McAllen; Alan T Davis; Bruce W Bonnell; James E Hoogeboom Journal: Am J Surg Date: 2005-03 Impact factor: 2.565
Authors: Heather Payne; Andrew Adamson; Amit Bahl; Jonathan Borwell; David Dodds; Catherine Heath; Robert Huddart; Rhona McMenemin; Prashant Patel; John L Peters; Andrew Thompson Journal: BJU Int Date: 2013-11 Impact factor: 5.588